Evaxion Biotech A/S
EVAX
$1.65
$0.063.77%
NASDAQ
| 12/31/2024 | 06/30/2024 | 12/31/2023 | 09/30/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 122.00K | 154.00K | 73.00K | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 122.00K | 154.00K | 73.00K | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 122.00K | 154.00K | 73.00K | -- | -- |
| SG&A Expenses | 1.89M | 1.98M | 2.14M | 2.93M | 2.93M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.15M | 4.74M | 4.44M | 5.76M | 5.76M |
| Operating Income | -4.02M | -4.58M | -4.36M | -5.76M | -5.76M |
| Income Before Tax | -3.90M | -6.40M | -4.70M | -5.87M | -5.87M |
| Income Tax Expenses | -275.00K | -199.00K | -177.00K | -194.00K | -194.00K |
| Earnings from Continuing Operations | -3.63M | -6.20M | -4.52M | -5.68M | -5.68M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.63M | -6.20M | -4.52M | -5.68M | -5.68M |
| EBIT | -4.02M | -4.58M | -4.36M | -5.76M | -5.76M |
| EBITDA | -3.93M | -4.48M | -4.27M | -5.56M | -5.56M |
| EPS Basic | -169.13 | -300.00 | -385.47 | -525.00 | -21.00 |
| Normalized Basic EPS | -2.27 | -3.87 | -5.01 | -6.79 | -1.36 |
| EPS Diluted | -169.13 | -300.00 | -385.47 | -525.00 | -21.00 |
| Normalized Diluted EPS | -2.27 | -3.87 | -5.01 | -6.79 | -1.36 |
| Average Basic Shares Outstanding | 1.07M | 1.03M | 586.70K | 540.80K | 2.70M |
| Average Diluted Shares Outstanding | 21.40K | 20.60K | 11.70K | 10.80K | 270.30K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |